Monopar Therapeutics Inc
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors express… Read more
Monopar Therapeutics Inc (MNPR) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.015x
Based on the latest financial reports, Monopar Therapeutics Inc (MNPR) has a cash flow conversion efficiency ratio of -0.015x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.09 Million) by net assets ($141.56 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Monopar Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2015–2024)
This chart illustrates how Monopar Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Monopar Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Monopar Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Shenzhen Changfang Light Emitting
SHE:300301
|
-0.028x |
|
Alcor Micro
TWO:8054
|
0.010x |
|
Youdao Inc
NYSE:DAO
|
0.389x |
|
KRISPY KREME DL-01
F:9YM
|
N/A |
|
Zhejiang Whyis Technology Co.Ltd.
SHE:301218
|
N/A |
|
Henan Rebecca Hair Products Co Ltd
SHG:600439
|
0.031x |
|
Parke Bancorp Inc
NASDAQ:PKBK
|
0.035x |
|
Qtone Education Group Guangdong Ltd
SHE:300359
|
-0.005x |
Annual Cash Flow Conversion Efficiency for Monopar Therapeutics Inc (2015–2024)
The table below shows the annual cash flow conversion efficiency of Monopar Therapeutics Inc from 2015 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $55.04 Million | $-6.40 Million | -0.116x | +91.73% |
| 2023-12-31 | $5.59 Million | $-7.86 Million | -1.406x | -96.30% |
| 2022-12-31 | $10.09 Million | $-7.23 Million | -0.716x | -85.45% |
| 2021-12-31 | $18.94 Million | $-7.32 Million | -0.386x | -30.03% |
| 2020-12-31 | $15.69 Million | $-4.66 Million | -0.297x | -24.33% |
| 2019-12-31 | $12.63 Million | $-3.02 Million | -0.239x | +42.73% |
| 2018-12-31 | $6.92 Million | $-2.89 Million | -0.417x | -52.76% |
| 2017-12-31 | $9.62 Million | $-2.63 Million | -0.273x | +35.27% |
| 2016-12-31 | $2.83 Million | $-1.19 Million | -0.422x | -82.64% |
| 2015-12-31 | $2.75 Million | $-636.33K | -0.231x | -- |